{"id":"8538749fa2b2","type":"article","url":"https://hartvaat.nl/2022/02/01/luseogliflozine-en-geschat-plasmavolume-bij-hfpef/","title":"Luseogliflozine en geschat plasmavolume bij HFpEF","title_en":"Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13683","source_url":"https://doi.org/10.1002/ehf2.13683","authors":["Mitsutaka Nakashima","Toru Miyoshi","Kentaro Ejiri","Hajime Kihara","Yoshiki Hata","Toshihiko Nagano","Atsushi Takaishi","Hironobu Toda","Seiji Nanba","Yoichi Nakamura","Satoshi Akagi","Satoru Sakuragi","Taro Minagawa","Yusuke Kawai","Nobuhiro Nishii","Soichiro Fuke","Masaki Yoshikawa","Kazufumi Nakamura","Hiroshi Ito"],"significance":5,"published":"2022-02-01","source_date":"2022-02-01","image":"","kennis":[],"congress":"","summary_en":"This study showed that luseogliflozin reduces estimated plasma volume in HFpEF patients, demonstrating the diuretic-natriuretic mechanism of SGLT2 inhibition in the preserved ejection fraction phenotype.","created":"2026-07-03T10:29:37Z","updated":"2026-07-03T13:28:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie naar de effecten van luseogliflozine op geschat plasmavolume bij HFpEF.","abstract_original":"AIMS: Sodium glucose co-transporter 2 inhibitors have diuretic effects in both patients with glycosuria and with natriuresis. We sought to assess the effect of luseogliflozin on estimated plasma volume (ePV) in patients with type 2 diabetes and heart failure with preserved ejection fraction (HFpEF). METHODS AND RESULTS: This study was a post-hoc analysis of the MUSCAT-HF trial (UMIN000018395), a multicentre, prospective, open-label, randomized controlled trial that assessed the effect of 12 weeks of luseogliflozin (2.5 mg, once daily, n = 83) as compared with voglibose (0.2 mg, three times daily, n = 82) on the reduction in brain natriuretic peptide (BNP) in patients with type 2 diabetes and HFpEF. The analysis compared the change in ePV calculated by the Straus formula from baseline to Weeks 4, 12, and 24, using a mixed-effects model for repeated measures. We also estimated the association between changes in ePV and changes in other clinical parameters, including BNP levels. Luseogliflozin significantly reduced ePV as compared to voglibose at Week 4 {adjusted mean group-difference -6.43% [95% confidence interval (CI): -9.11 to -3.74]}, at Week 12 [-8.73% (95%CI: -11.40 to -6.05)], and at Week 24 [-11.02% (95%CI: -13.71 to -8.33)]. The effect of luseogliflozin on these parameters was mostly consistent across various patient clinical characteristics. The change in ePV at Week 12 was significantly associated with log-transformed BNP (r = 0.197, P = 0.015) and left atrial volume index (r = 0.283, P = 0.019). CONCLUSIONS: Luseogliflozin significantly reduced ePV in patients with type 2 diabetes and HFpEF, as compared with voglibose. The reduction of intravascular volume by luseogliflozin may provide clinical benefits to patients with type 2 diabetes and HFpEF."}